EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.

Slides:



Advertisements
Similar presentations
17 September 2007ISO TC215 WG6 Brisbane1 Identification of Medicinal Products & Pharmacovigilance Task Forces.
Advertisements

US-EU Regulatory Cooperation Approaches and Experiences Jim Sanford, Office of the U.S. Trade Representative (USTR) Simon Holland, European Commission.
ENQA’S CONSULTATIVE MEMBERSHIP IN THE BFUG - WHAT DOES IT ENTAIL
December 2005 EuP Directive : A Framework for setting eco-design requirements for energy-using products European Commission.
July 2002 EU Conference on 3Rs Animal Experimentation - a controversial issue.
EPAA Annual conference November Regulatory acceptance of alternative approaches for pharmaceuticals Jean-Marc Vidal Safety & Efficacy of Human Medicines.
1 n European Commission Third Global Congress on Combating Counterfeiting and Piracy Geneva – 30 and 31 January 2007 The European Union: Coordination and.
Energy Proposal for a Council Directive amending Directive 2009/71/EURATOM establishing a Community framework for the nuclear safety of nuclear installations.
ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.
Slide 1 IMPACT INDICATORS Agenda Point 2 Meeting of Network of experts on Multi- Annual National Control Plans and Annual Reports (Articles OF Regulation.
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
Lord Mogg Chair of ERGEG Florence Forum June 2009 Implementation of the Third Energy Package.
PRESENTATION The Structured Dialogue. What? A participative process for young people and decision-makers to discuss and elaborate recommendations jointly.
EFSA MANAGEMENT PLAN 2008 The Management Plan
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Prequalification programme: Priority essential.
What is ICH? ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific.
Senior Regulators Meeting The future of the IRRS Programme: Enhancing the Effectiveness of the Regulatory Body Ramzi Jammal, Executive Vice-President and.
The European Code of Conduct on Partnership Teresa EPALZA European Commission DG Employment, Social Affairs and Inclusion.
Terezia Sinkova EFSA The new EU Food Safety Agency.
Euei1. 2 Facilitation Workshop and Policy Dialogue Maputo April 2005 Enrico Strampelli European Commission DG Development.
The European Qualifications Framework for Lifelong Learning – Update on Recent Developments ReferNet Meeting 22 January 2009.
ITUC Human and Trade Union Rights Report of the PERC HTUR Network Meeting PERC HTUR Network PERC Summer School, Bratislava September
PRESENTATION IV Cycle of the Structured Dialogue.
ENTERPRISE AND INDUSTRY DIRECTORATE GENERAL European Commission 1 PECAs David Eardley DG Enterprise and Industry European Commission Tel: 032 (2)
1 DG Enterprise & Industry European Commission Conference on Better Regulation: Practical Steps Forward Reykjavík 6 June 2006 OVERVIEW OF THE BETTER REGULATION.
The EU Commission's legislative proposal on implementing the Nagoya Protocol in the Union I.Background II.Preparatory work done in support of the proposal.
Processus de Rabat / Rabat Process Session 4: Monitoring the Roadmap of the Dakar Strategy MEETING ON THE STRENGTHENING OF POLITICAL DECISION-MAKING BASED.
BMH CLINICAL GUIDELINES IN EUROPE. OUTLINE Background to the project Objectives The AGREE Instrument: validation process and results Outcomes.
European Commission European social dialogue and Labour Law Transnational company agreements Evelyne Pichot European Commission Roma, September 2009.
1 The Future Role of the Food and Veterinary Office M.C. Gaynor, Director, FVO EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate.
EC actions against the rising threats from Antimicrobial Resistance
FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on the Common Technical Document and Possibilities for New Topics.
1 Item 2.1.b of the agenda IT Governance in the ESS and related issues Renewal of mandates STNE Adam WROŃSKI Eurostat, Unit B5.
Flood Task Force Report to the 4th Meeting of the Parties 20 to 22 November 2006 Bonn.
Partnership Health: Evaluation and possibilities for an adapted structure Agenda item 11 Madhavi Bajekal, ONS (UK) PH coordinator Directors of Social Statistics.
Impact analysis during the harmonisation process with the EU and effects on Lithuanian economy Giedrius Kadziauskas, Senior Policy analyst 23 rd Fabruary.
Tripartite Declaration of Principles concerning Multinational Enterprises and Social Policy (MNE Declaration) Multinational enterprises and social policy.
Special Meeting on Procedures for Information Exchange November 7, 2007 Geneva Session 1 Anne Meininger United States USA WTO TBT Enquiry Point.
VICH General Principles and current update of VICH Outreach Forum activity 1.
VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.
-What is VICH, History and Objectives Hervé MARION, DVM VICH Secretariat.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.
Workshop on “EU Enlargement: Regulatory Convergence in Non-acceding Countries” Athens 7 – 8 November 2003 Regulatory Convergence and Technical Standards.
Harmonised use of accreditation for assessing the competence of various Conformity Assessment Bodies Dr Andreas Steinhorst, EA ERA workshop 13 April 2016,
Towards a European Shared Environmental Information System in Support of Environmental Policies: INSPIRE: an Inspired revolution for a knowledge-based.
Korea Responsible Care Council RESPONSIBLE CARE ® in KOREA March 2001 By KOREA RESPONSIBLE CARE COUNCIL.
Slide 1 The contribution of a world-class regulatory environment to the future of the industry in Ireland Pat O’Mahony Chief Executive, Irish Medicines.
Trade Union Training on the Validation of the training manual entitled “Union Training on Occupational Safety and Health” OCCUPATIONAL SAFETY & HEALTH:
Paediatric Medicine: The Paediatric Investigation Plan
EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
STRESS TESTS and TAIWAN PEER REVIEW PROCESS
Michelle Limoli, Pharm.D.
Corporate Restructuring And Workers' involvement
EU Reference Centres for Animal Welfare
What is ICH? ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific.
The importance of dialogue between regulators
The 3Rs principles for safety testing of human and veterinary medicines A view on the EU regulatory developments in 3Rs (replacement, reduction, refinement)
Nick Bonvoisin Secretary to the Convention on the
ECVAM as EU-RL according to 2010/63
Institutional changes The role of Bilateral Oversight Boards
SOCIAL DIALOGUE WITHIN EUPAN
SOCIAL DIALOGUE WITHIN THE SCOPE OF EUPAN
Management of Natura 2000 Sites
Jørgen Friis, ETSI VP SES
EU Marine Strategy DG Environment B.1.
Review of Decision 2010/477/EU and MSFD Annex III
Health and safety at work in the EU
Abnormal toxicity test (ATT) -
Presentation transcript:

EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance

EPAA Conference 2006 Workshop Regulatory Acceptance, June 2007 Highlighted the importance of acceptance at a global level Addressed a plea to the EU to maintain alternative approaches on the agenda of the regulatory dialogue with trading partners

Action currently being undertaken Mainly in a multilateral context On the basis of procedures that, according to sectors, are more or less formally established Progress being verified in regulatory dialogue on a bilateral level

Chemicals Main forum for discussion is the OECD Principle of Mutual Acceptance OECD guidance N° 34 OECD Test Guidelines, adopted as testing methods in EU regulation for chemicals

Pharmaceuticals At the request of the Commission, the EMEA has conducted a review of current international (ICH) non- clinical guidelines to see whether they were up to date and whether their was scope to promote the 3Rs agenda. Based on the Safety Working Parties scientific review, the European Commission then proposed a review of the ICH guidelines by ICH A formal review started at the June 2006 ICH meeting

ICH Steering Committee May Confirmed its commitment to the 3Rs agenda, with a view to the replace, reduce or refine animal testing when drafting new or revising existing guidelines. Is committed to ensuring that groups working on ongoing and new topics document their impact on animal testing

From the EU initiated ICH review, three ICH guidelines are under revision carcinogenicity, genotoxicity and the non-clinical studies necessary for human trials guidelines. The European Commission is confident that the ongoing ICH work will have a positive impact for the three-Rs agenda

Cooperation with validation bodies First contacts took place between the non-clinical safety experts working within ICH and the organisations for Validation of Alternative Methods in the three regions Update on ongoing activities regarding alternative methods to animal testing and looking for ways to increase mutual understanding and collaboration

European Directorate for the Quality of Medicines & HealthCare, EDQM Council of Europe European Pharmacopeia In accordance with the European Convention …… the Ph. Eur. Commission (Council of Europe) is committed to the reduction of animal usage, wherever possible, in pharmacopoeia testing and encourages those associated with its work to seek alternative procedures. An alternative or modified method is adopted by the Commission once it has been clearly demonstrated that it offers satisfactory control for pharmacopoeial purposes

European Directorate for the Quality of Medicines & HealthCare, EDQM Council of Europe Progress has been made in implementing the 3Rs EDQM has initiated an enquiry aimed at verifying to what extent 3R methods have been transposed and are being implemented by stakeholders Collaboration has been established between EDQM and ECVAM.

Cosmetics First meeting European Commission, FDA, Health Canada and the Ministry of Health, Labour and Welfare, Japan, in September, 2007 in Brussels to discuss regulatory issues relating to cosmetic products. Establishment of the ICCR, the "International Cooperation on Cosmetic Regulation", for information exchange aiming at ensuring safety of cosmetic products through international cooperation

Alternative methods identified as a priority Intensive collaboration and communication in the design, execution, and peer review of validation studies should be further strengthened ICCVAM, ECVAM, JaCVAM and Canada should address this issue and propose options to ensure a collaborative approach They should be supported by scientific experts from the regulatory bodies

Regulatory authorities committed to implementation of 3R approaches Need to involve regulators in validation processes Experience suggests that if there are substantial discrepancies between U.S. and EU at the regulation stage, they are usually due to different appraisals at the peer review stage Cooperation, also on peer review, might be strengthened by an International Council of Validation Bodies Overall assessment